Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;32(3):101-5.
doi: 10.12938/bmfh.32.101. Epub 2013 Jul 25.

The Effect of Lactic Acid Bacteria-fermented Soybean Milk Products on Carrageenan-induced Tail Thrombosis in Rats

Seitaro Kamiya  1 , Masayoshi Ogasawara  1 , Masayuki Arakawa  1 , Masayori Hagimori  1
Affiliations

The Effect of Lactic Acid Bacteria-fermented Soybean Milk Products on Carrageenan-induced Tail Thrombosis in Rats

Seitaro Kamiya et al. Biosci Microbiota Food Health. 2013.

Abstract

Thrombosis is characterized by congenital and acquired procatarxis. Lactic acid bacteria-fermented soybean milk products (FS-LAB) inhibit hepatic lipid accumulation and prevent atherosclerotic plaque formation. However, the therapeutic efficacy of FS-LAB against thrombosis has yet to be investigated. In this study, FS-LAB were administered subcutaneously into the tails of rats, with the subsequent intravenous administration of κ-carrageenan 12 hr after the initial injection. In general, administration of κ-carrageenan induces thrombosis. The length of the infarcted tail regions was significantly shorter in the rats administered a single-fold or double-fold concentration of the FS-LAB solution compared with the region in control rats. Therefore, FS-LAB exhibited significant antithrombotic effects. Our study is the first to characterize the properties of FS-LAB and, by testing their efficacy on an in vivo rat model of thrombosis, demonstrate the potency of their antithrombotic effect.

Keywords: fermented soybean milk products; lactic acid bacteria; rat tail; thrombosis; κ-carrageenan.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Photographs of fibrin clots 8 hr after mixing fibrinogen and thrombin. The concentration of FS-LAB are indicate as 0 ×, 0.1 ×, 0.2 ×, 0.5 ×, 1.0 × and 2.0 ×.
Fig. 2.
Fig. 2.
Effect of FS-LAB on the mean length of the infarcted tail regions. The horizontal axis shows the time elapsed after the κ-carrageenan injection; κ-carrageenan was injected intravenously 12 hr after subcutaneous injection of FS-LAB solution or PBS. Statistical analysis was performed using ANOVA with a post hoc Tukey test. Significant differences in the mean infarct length between 2× and 1× FS-LAB-administered groups are indicated by *p<0.05. The mean length of the infarcted regions of the FS-LAB-administered groups (2× and 1×) was compared with that of the PBS-administered group at 6, 24 and 48 hr. The PBS column represents the mean value ± SD of 7 measurements. The 1× FS-LAB column represents the mean ± SD of 6 measurements. The 2× FS-LAB column represents the mean value ± SD of 7 measurements.
Fig. 3.
Fig. 3.
Photographs of infarcted rat tails 24 hr after κ-carrageenan was injected for induction of thrombosis. 2×: rat tail after subcutaneous pre-injection with 2× FS-LAB 12 hr before κ-carrageenan injection. 1×: rat tail after subcutaneous pre-injection with 1× FS-LAB 12 hr before κ-carrageenan injection. PBS: rat tail after subcutaneous pre-injection with PBS 12 hr before κ-carrageenan injection.
See this image and copyright information in PMC

References

    1. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. 2000. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 65: 45–49 - PubMed
    1. Helley D, Besmond C, Ducrocq R, da Silva F, Guillin MC, Bezeaud A, Elion J. 1997. Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease. Hum Genet 100: 245–248 - PubMed
    1. Bice DE, Gruwell DG, Salvaggio JE, Hoffmann EO. 1972. Suppression of primary immunization by carrageenan - a macrophage toxic agent. Immunol Commun 1: 615–625 - PubMed
    1. Kod’ousek R, Jezdínský J, Krajcí D. 2007. Histological and ultrastructural changes of cardiomyocytes in experimental rats with tail thrombosis following subplantar application of carrageenin. Med Princ Pract 16: 360–366 - PubMed
    1. Hagimori M, Kamiya S, Yamaguchi Y, Arakawa M. 2009. Improving frequency of thrombosis by altering blood flow in the carrageenan-induced rat tail thrombosis model. Pharmacol Res 60: 320–323 - PubMed

LinkOut - more resources